文献速递妇科

同源重组状态及维利帕尼联合一线化疗在卵巢癌中的疗效:3期VELIA/GOG-3005研究探索性分析

Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
PubMed 文献 · Gynecol Oncol · 2021-12-11

3期VELIA试验纳入III-IV期卵巢癌患者,随机接受维利帕尼全程、维利帕尼仅联合化疗或安慰剂。在BRCA野生型患者中,维利帕尼全程组与对照组的PFS风险比在同源重组缺陷与熟练型亚组相似,第3周期时CA-125下降≥90%的比例在维利帕尼组更高(34% vs 23%,P=0.0004)。

要点

  • BRCA野生型卵巢癌中,维利帕尼全程组与对照组PFS风险比在同源重组缺陷(HR 0.76)与熟练型(HR 0.765)相似。
  • 第3周期时CA-125较基线下降≥90%的比例:维利帕尼汇总组34% vs 对照组23%(P=0.0004)。
  • 术后可测量病灶患者中,完全缓解率维利帕尼汇总组24% vs 对照组18%。

核心结论

  • 这些结果可能扩大PARP抑制剂在一线维持治疗中不符合其他试验资格患者的应用机会。

研究设计与样本

  • 3期VELIA试验(NCT02470585)将III-IV期卵巢癌女性随机分配至维利帕尼全程组、维利帕尼仅联合化疗组或安慰剂组。
  • 分层因素包括手术时机和胚系BRCA突变状态;同源重组缺陷状态以基因组不稳定评分33为界二分。
  • 联合治疗期间,基线和每周期检测CA-125;每9周评估影像学反应。
  • 随机化1140例患者,其中742例为BRCA野生型肿瘤(同源重组熟练型n=373;同源重组缺陷/BRCA野生型n=329)。

主要发现

  • BRCA野生型人群中,维利帕尼全程组与对照组的PFS风险比在同源重组缺陷/BRCA野生型组为22.9 vs 19.8个月(HR 0.76;95%CI 0.53-1.09),在同源重组熟练型组为15.0 vs 11.5个月(HR 0.765;95%CI 0.56-1.04)。
  • 第3周期时,CA-125较基线下降≥90%的比例在维利帕尼汇总组高于对照组(34% vs 23%;P=0.0004),尤其在BRCA野生型和同源重组熟练型亚组中更高。
  • 术后可测量病灶患者中,完全缓解率维利帕尼汇总组为24%,对照组为18%。

临床怎么用

  • 作者认为,这些结果可能扩大PARP抑制剂在一线维持治疗中不符合其他试验资格患者的应用机会。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy. METHODS: Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks. RESULTS: Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control. CONCLUSIONS: These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Swisher EM, Aghajanian C, O'Malley DM, et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2021. PMID: 34906376. doi:10.1016/j.ygyno.2021.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。